- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: MK-3475.
Displaying page 1 of 15.
EudraCT Number: 2016-004353-32 | Sponsor Protocol Number: GECP16/06 | Start Date*: 2017-09-01 |
Sponsor Name:Spanish Lung Cancer Group (SLCG/GECP) | ||
Full Title: Survival, quality of life and self-reported outcomes of elderly patients with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (MK-3475) in the first line setting | ||
Medical condition: First line treatment in PD-L1 positive advanced non-small cell lung cancer patients | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2014-002447-18 | Sponsor Protocol Number: MK3475-055 | Start Date*: 2015-09-23 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | ||
Full Title: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab | ||
Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003785-14 | Sponsor Protocol Number: 200249 | Start Date*: 2014-03-03 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004391-19 | Sponsor Protocol Number: 3475-010 | Start Date*: 2013-04-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Merck) | |||||||||||||
Full Title: A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) LT (Completed) HU (Completed) BE (Completed) ES (Completed) DK (Completed) DE (Completed) IT (Completed) NL (Completed) FR (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003030-17 | Sponsor Protocol Number: 3475-002 | Start Date*: 2012-11-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma | |||||||||||||
Medical condition: Advanced melanoma (unresectable or metastatic) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) NO (Completed) SE (Completed) IT (Completed) NL (Completed) FR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002009-40 | Sponsor Protocol Number: MK-3475-045 | Start Date*: 2014-09-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer | |||||||||||||
Medical condition: Metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) IT (Completed) DE (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) SE (Completed) DK (Completed) GB (Completed) PT (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000185-22 | Sponsor Protocol Number: 20110265 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
Medical condition: Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Completed) IT (Prematurely Ended) FI (Prematurely Ended) CZ (Completed) PT (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000681-55 | Sponsor Protocol Number: 3475-022 | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma | ||||||||||||||||||
Medical condition: advanced or metastatic melanoma - all parts of the trial advanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004566-28 | Sponsor Protocol Number: MK-3475-224 | Start Date*: 2016-06-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224) | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003359-23 | Sponsor Protocol Number: GEM-PEMBRESID | Start Date*: 2015-12-16 | |||||||||||
Sponsor Name:FundaciĆ³n Pethema | |||||||||||||
Full Title: Clinical Trial of Phase II, Open Label, Multicenter, of the monoclonal antibody anti-PD1 Pembrolizumab (MK-3475) as consolidation therapy in patients with multiple myeloma with residual disease aft... | |||||||||||||
Medical condition: Patients with multiple myeloma with residual disease after treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000323-25 | Sponsor Protocol Number: MK-3475-024 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: Non-Small Cell Lung Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) IE (Completed) HU (Completed) DE (Completed) ES (Completed) BE (Completed) NL (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002206-20 | Sponsor Protocol Number: MK-3475-052 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer | |||||||||||||
Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001749-26 | Sponsor Protocol Number: MK-3475-040 | Start Date*: 2014-11-21 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer | |||||||||||||
Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) LT (Completed) DE (Completed) BE (Completed) PT (Ongoing) NL (Completed) HU (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004907-10 | Sponsor Protocol Number: MK-3475-006 | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck) | |||||||||||||
Full Title: A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Adv... | |||||||||||||
Medical condition: Patients with advanced Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) FR (Completed) DE (Completed) NL (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001252-22 | Sponsor Protocol Number: MP-LALC | Start Date*: 2017-08-02 | |||||||||||
Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO | |||||||||||||
Full Title: Pembrolizumab (MK-3475) as maintainance unresectable stage III NSCLC after chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer). | |||||||||||||
Medical condition: unresectable stage IIIA/B Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005197-35 | Sponsor Protocol Number: S1404 | Start Date*: 2017-06-06 |
Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland | ||
Full Title: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma. | ||
Medical condition: High risk resected melanoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003717-34 | Sponsor Protocol Number: MK-7902-010 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and... | |||||||||||||
Medical condition: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) HU (Ongoing) DE (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002312-41 | Sponsor Protocol Number: MK-3475-365 | Start Date*: 2016-10-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | |||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Ongoing) DK (Ongoing) IE (Ongoing) IT (Ongoing) PL (Ongoing) NL (Ongoing) AT (Ongoing) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001832-21 | Sponsor Protocol Number: MK-3475-671 | Start Date*: 2018-02-28 | |||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||||||||||||
Full Title: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resecta... | |||||||||||||||||||||||
Medical condition: Neoadjuvant/Adjuvant treatment for participants with Resectable Stage II or IIIA-B (N2) NSCLC | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Ongoing) FR (Ongoing) PL (Ongoing) LT (Trial now transitioned) LV (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003644-40 | Sponsor Protocol Number: MK-3475-199 | Start Date*: 2016-06-06 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199) | |||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) IE (Completed) DE (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) PL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.